Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Randomized, Double-blind, Parallel, Positive-controlled Phase III Clinical Trial to Evaluate the Therapeutic Equivalence of SYN008 Versus Xolair® in the Treatment of Patients With Refractory Chronic Spontaneous Urticaria

NCT04944602 is registered in ClinicalTrials.gov with CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. as lead sponsor.

NCT NCT04944602
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04944602 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Randomized, Double-blind, Parallel, Positive-controlled Phase III Clinical Trial to Evaluate the Therapeutic Equivalence of SYN008 Versus Xolair® in the Treatment of Patients With Refractory Chronic Spontaneous Urticaria
Lead sponsor
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Phase
Phase 3
Overall status
Unknown status
Start date
July 31, 2021
Completion date
June 30, 2023
Enrollment
340 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

chronic spontaneous urticaria